Osteosarcoma - mifamurtide: final appraisal determination 2
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on osteosarcoma - mifamurtide and submitted it to the Institute.
The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.
Please note that the appeal period for this appraisal will close at 5pm on 21 September 2011.
Osteosarcoma - mifamurtide: final appraisal determination document
Osteosarcoma - mifamurtide: letter from The Department of Health
Osteosarcoma - mifamurtide: manufacturer submission from Takeda UK
Osteosarcoma - mifamurtide: Evidence Review Group critique prepared by School of Health and Related Research (ScHARR), The University of Sheffield
Osteosarcoma - mifamurtide: Evidence Review Group critique - factual accuracy check
Osteosarcoma - mifamurtide: expert statements August 2011
Osteosarcoma - mifamurtide: discounting of health benefits in special circumstances
This page was last updated: 06 September 2011